Last reviewed · How we verify

Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole

Fu Jen Catholic University Hospital · FDA-approved active Small molecule Quality 5/100

Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole is a Small molecule drug developed by Fu Jen Catholic University Hospital. It is currently FDA-approved.

At a glance

Generic nameLansoprazole, Amoxicillin, Clarithromycin and Metronidazole
SponsorFu Jen Catholic University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole

What is Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole?

Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole is a Small molecule drug developed by Fu Jen Catholic University Hospital.

Who makes Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole?

Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole is developed and marketed by Fu Jen Catholic University Hospital (see full Fu Jen Catholic University Hospital pipeline at /company/fu-jen-catholic-university-hospital).

What development phase is Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole in?

Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole is FDA-approved (marketed).

Related